{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:35:02Z","timestamp":1776479702836,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00228-022-03376-1","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T18:04:47Z","timestamp":1662228287000},"page":"1727-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"78","author":[{"given":"Jianfeng","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"3376_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","volume":"377","author":"MP Bauer","year":"2011","unstructured":"Bauer MP, Notermans DW, van Benthem BHB et al (2011) Clostridium difficile infection in Europe: a hospital-based survey. Lancet Lond Engl 377:63\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(10)61266-4","journal-title":"Lancet Lond Engl"},{"key":"3376_CR2","first-page":"11","volume":"131B","author":"F Tytgat","year":"1980","unstructured":"Tytgat F (1980) Rate of isolation of \u201cC. difficile\u201d from stools of hospitalized patients: susceptibility of 75 strains (author\u2019s transl). Ann Microbiol (Paris) 131B:11\u201320","journal-title":"Ann Microbiol (Paris)"},{"key":"3376_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/s0140-6736(83)91036-x","volume":"2","author":"DG Teasley","year":"1983","unstructured":"Teasley DG, Gerding DN, Olson MM et al (1983) Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet Lond Engl 2:1043\u20131046. https:\/\/doi.org\/10.1016\/s0140-6736(83)91036-x","journal-title":"Lancet Lond Engl"},{"key":"3376_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","volume":"22","author":"C Wenisch","year":"1996","unstructured":"Wenisch C, Parschalk B, Hasenh\u00fcndl M et al (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis Off Publ Infect Dis Soc Am 22:813\u2013818. https:\/\/doi.org\/10.1093\/clinids\/22.5.813","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"3376_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/cid\/cir830","volume":"54","author":"AA Venugopal","year":"2012","unstructured":"Venugopal AA, Johnson S (2012) Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis Off Publ Infect Dis Soc Am 54:568\u2013574. https:\/\/doi.org\/10.1093\/cid\/cir830","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"3376_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/2040622313511285","volume":"5","author":"K Mullane","year":"2014","unstructured":"Mullane K (2014) Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis 5:69\u201384. https:\/\/doi.org\/10.1177\/2040622313511285","journal-title":"Ther Adv Chronic Dis"},{"issue":"Suppl 2","key":"3376_CR7","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/cis453","volume":"55","author":"F Babakhani","year":"2012","unstructured":"Babakhani F, Bouillaut L, Gomez A et al (2012) Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis Off Publ Infect Dis Soc Am 55(Suppl 2):S162-169. https:\/\/doi.org\/10.1093\/cid\/cis453","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"3376_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S et al (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis Off Publ Infect Dis Soc Am 66:e1\u2013e48. https:\/\/doi.org\/10.1093\/cid\/cix1085","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"3376_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/13696998.2017.1302946","volume":"20","author":"M Watt","year":"2017","unstructured":"Watt M, Dinh A, Le Monnier A, Tilleul P (2017) Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ 20:678\u2013686. https:\/\/doi.org\/10.1080\/13696998.2017.1302946","journal-title":"J Med Econ"},{"key":"3376_CR10","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1128\/AAC.00939-15","volume":"59","author":"JC Gallagher","year":"2015","unstructured":"Gallagher JC, Reilly JP, Navalkele B et al (2015) Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother 59:7007\u20137010. https:\/\/doi.org\/10.1128\/AAC.00939-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3376_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):1\u20131","journal-title":"Syst Rev"},{"key":"3376_CR12","unstructured":"Wells G, Shea B, O\u2019Connell D et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 21"},{"key":"3376_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jcpt.12771","volume":"44","author":"JD Tieu","year":"2019","unstructured":"Tieu JD, Williams RJ, Skrepnek GH, Gentry CA (2019) Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther 44:220\u2013228. https:\/\/doi.org\/10.1111\/jcpt.12771","journal-title":"J Clin Pharm Ther"},{"key":"3376_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/phar.2503","volume":"41","author":"N Patel","year":"2021","unstructured":"Patel N, Lowry C, Morgenson D et al (2021) Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans\u2019 affairs patients with infections due to Clostridioides difficile. Pharmacotherapy 41:212\u2013219. https:\/\/doi.org\/10.1002\/phar.2503","journal-title":"Pharmacotherapy"},{"key":"3376_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/jcpt.13387","volume":"46","author":"A Rinaldi","year":"2021","unstructured":"Rinaldi A, Reed EE, Stevenson KB et al (2021) Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent Clostridioides difficile. J Clin Pharm Ther 46:993\u2013998. https:\/\/doi.org\/10.1111\/jcpt.13387","journal-title":"J Clin Pharm Ther"},{"key":"3376_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0018578719844165","volume":"55","author":"BB Summers","year":"2020","unstructured":"Summers BB, Yates M, Cleveland KO et al (2020) Fidaxomicin compared with oral vancomycin for the treatment of severe Clostridium difficile-associated diarrhea: a retrospective review. Hosp Pharm 55:268\u2013272. https:\/\/doi.org\/10.1177\/0018578719844165","journal-title":"Hosp Pharm"},{"key":"3376_CR17","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/AAC.01120-13","volume":"57","author":"DS Clutter","year":"2013","unstructured":"Clutter DS, Dubrovskaya Y, Merl MY et al (2013) Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 57:4501\u20134505. https:\/\/doi.org\/10.1128\/AAC.01120-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3376_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijid.2020.11.004","volume":"103","author":"S Polivkova","year":"2021","unstructured":"Polivkova S, Krutova M, Capek V et al (2021) Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - an observational cohort study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 103:226\u2013233. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.004","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"3376_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmi.2018.12.007","volume":"25","author":"CA Gentry","year":"2019","unstructured":"Gentry CA, Nguyen PK, Thind S et al (2019) Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 25:987\u2013993. https:\/\/doi.org\/10.1016\/j.cmi.2018.12.007","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"3376_CR20","doi-asserted-by":"publisher","first-page":"w20173","DOI":"10.4414\/smw.2020.20173","volume":"150","author":"S Haubitz","year":"2020","unstructured":"Haubitz S, Bartlom\u00e9 N, Bucheli Laffer E et al (2020) Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study. Swiss Med Wkly 150:w20173. https:\/\/doi.org\/10.4414\/smw.2020.20173","journal-title":"Swiss Med Wkly"},{"key":"3376_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.hemonc.2018.05.001","volume":"11","author":"L Prohaska","year":"2018","unstructured":"Prohaska L, Mahmoudjafari Z, Shune L et al (2018) Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther 11:233\u2013240. https:\/\/doi.org\/10.1016\/j.hemonc.2018.05.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"3376_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/HCO.0b013e32834b9ee6","volume":"26","author":"BG Leshnower","year":"2011","unstructured":"Leshnower BG, Guyton RA, Puskas JD (2011) Why randomized clinical trials are important to cardiac surgeons. Curr Opin Cardiol 26:536\u2013540. https:\/\/doi.org\/10.1097\/HCO.0b013e32834b9ee6","journal-title":"Curr Opin Cardiol"},{"key":"3376_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/eurheartj\/ehi731","volume":"27","author":"M Hordijk-Trion","year":"2006","unstructured":"Hordijk-Trion M, Lenzen M, Wijns W et al (2006) Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 27:671\u2013678. https:\/\/doi.org\/10.1093\/eurheartj\/ehi731","journal-title":"Eur Heart J"},{"key":"3376_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamainternmed.2019.1501","volume":"179","author":"B Smyth","year":"2019","unstructured":"Smyth B, Haber A, Trongtrakul K et al (2019) Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis. JAMA Intern Med 179:1316\u20131324. https:\/\/doi.org\/10.1001\/jamainternmed.2019.1501","journal-title":"JAMA Intern Med"},{"key":"3376_CR25","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","volume":"48","author":"G Ntaios","year":"2017","unstructured":"Ntaios G, Papavasileiou V, Makaritsis K et al (2017) Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 48:2494\u20132503. https:\/\/doi.org\/10.1161\/STROKEAHA.117.017549","journal-title":"Stroke"},{"issue":"1","key":"3376_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jiac.2019.07.005","volume":"26","author":"H Okumura","year":"2020","unstructured":"Okumura H, Fukushima A, Taieb V, Shoji S, English M (2020) Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis. J Infect Chemother 26(1):43\u201350. https:\/\/doi.org\/10.1016\/j.jiac.2019.07.005","journal-title":"J Infect Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03376-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:07:56Z","timestamp":1665126476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3376"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03376-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}